82 related articles for article (PubMed ID: 421493)
21. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review.
Kang HY; Valerio L; Bahadoran P; Ortonne JP
Am J Clin Dermatol; 2009; 10(4):251-60. PubMed ID: 19489658
[TBL] [Abstract][Full Text] [Related]
22. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
[TBL] [Abstract][Full Text] [Related]
23. Dyspigmentation, skin physiology, and a novel approach to skin lightening.
Draelos Z; Dahl A; Yatskayer M; Chen N; Krol Y; Oresajo C
J Cosmet Dermatol; 2013 Dec; 12(4):247-53. PubMed ID: 24305422
[TBL] [Abstract][Full Text] [Related]
24. The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial.
Christiansen JV; Foged E; Holm P; Jørgensen AS; Reymann F
Dermatologica; 1985; 170(4):195-8. PubMed ID: 3888709
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial to compare calcipotriol with betamethasone valerate for the treatment of cutaneous lichen planus.
Theng CT; Tan SH; Goh CL; Suresh S; Wong HB; Machin D;
J Dermatolog Treat; 2004 Jun; 15(3):141-5. PubMed ID: 15204145
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study.
Shin H; Kwon OS; Won CH; Kim BJ; Lee YW; Choe YB; Ahn KJ; Eun HC
J Dermatol; 2009 Mar; 36(3):131-7. PubMed ID: 19335686
[TBL] [Abstract][Full Text] [Related]
27. Topical chemotherapy of pigment abnormalities in surgical patients.
Gilchrest BA; Goldwyn RM
Plast Reconstr Surg; 1981 Apr; 67(4):435-9. PubMed ID: 7208685
[TBL] [Abstract][Full Text] [Related]
28. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines.
Jarratt M
Cutis; 2004 Nov; 74(5):319-22. PubMed ID: 15605971
[TBL] [Abstract][Full Text] [Related]
29. Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies.
Gomez EC; Kaminester L; Frost P
Arch Dermatol; 1977 Sep; 113(9):1196-202. PubMed ID: 332089
[TBL] [Abstract][Full Text] [Related]
30. Betamethasone dipropionate (0.05)% plus chinoform (3%) cream against betamethasone valerate (0.1%) plus chinoform cream (3%) in secondarily infected dermatoses.
Chattopadhyay SP; Arora PN; Anand S; Sharma SD
Indian J Dermatol; 1987 Jul; 32(3):73-6. PubMed ID: 2973437
[No Abstract] [Full Text] [Related]
31. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation.
Cook-Bolden FE; Hamilton SF
Cutis; 2008 Apr; 81(4):365-71. PubMed ID: 18491487
[TBL] [Abstract][Full Text] [Related]
32. Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis.
Callen J
Cutis; 1996 Feb; 57(2 Suppl):45-50. PubMed ID: 8646870
[TBL] [Abstract][Full Text] [Related]
33. Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment.
Wilson LM; Reid CM
Australas J Dermatol; 2004 Aug; 45(3):184-5. PubMed ID: 15250900
[TBL] [Abstract][Full Text] [Related]
34. Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis.
Dhawan SS; Blyumin ML; Pearce DJ; Feldman SR
J Drugs Dermatol; 2005; 4(2):228-30. PubMed ID: 15776784
[TBL] [Abstract][Full Text] [Related]
35. [Testing the loss of efficacy (tachyphylaxis) during external steroid application].
Koch EM; Jurgovsky E
Hautarzt; 1985 Mar; 36(3):146-9. PubMed ID: 3997512
[TBL] [Abstract][Full Text] [Related]
36. [Hydrocortisone butyrate (Locoid) compared with betamethasone valerate. A controlled clinical trail].
Thormann J
Ugeskr Laeger; 1976 Jan; 138(4):214-6. PubMed ID: 766347
[No Abstract] [Full Text] [Related]
37. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies.
Kang WH; Chun SC; Lee S
J Dermatol; 1998 Sep; 25(9):587-96. PubMed ID: 9798345
[TBL] [Abstract][Full Text] [Related]
38. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream.
Adigun CG; Pandya AG
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):486-7. PubMed ID: 18721216
[No Abstract] [Full Text] [Related]
39. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
Draelos Z
Dermatol Surg; 2011 Jan; 37(1):126-7. PubMed ID: 21214668
[No Abstract] [Full Text] [Related]
40. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety.
Deo KS; Dash KN; Sharma YK; Virmani NC; Oberai C
Indian J Dermatol; 2013 Jul; 58(4):281-5. PubMed ID: 23918998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
